Lokathi Therapeutics

Lōkahi Therapeutics is a private, pre-revenue biotech leveraging a unique 'Actual Intelligence (ai²)' operating philosophy to identify and advance distressed or overlooked clinical assets. Its lead candidate, Apitox, targets inflammation and pain, initially in osteoarthritis, representing a non-opioid alternative in a large market. The company is actively seeking licensing and acquisition opportunities to build its pipeline and is led by a team with expertise in development, finance, and technology.

Actual Intelligence (ai²) - A strategic operating framework emphasizing human expertise, cross-disciplinary insight, and clinical judgment to identify, evaluate, and advance distressed or overlooked therapeutic assets.

In osteoarthritis pain, Apitox would compete against NSAIDs, opioids, corticosteroids, and novel biologic therapies. As a business model, Lōkahi competes with other biotech 'vulture' funds and asset-centric companies that seek to in-license and develop deprioritized programs from larger pharmaceutical firms.